

Please join us for an upcoming discussion about AZSTARYSTM



serdexmethylphenidate
and dexmethylphenidate

26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules

the first and only ADHD treatment with a novel dexmethylphenidate-based prodrug^{1,2} and an immediate-release component for patients 6 years and older



FEATURED SPEAKER

Kenny Perez, MD, FAPA
Elevate Psychiatry
Miami, FL



WHEN

Friday, March 17, 2023
7:00 PM ET



WHERE

The Westin Richmond
6631 West Broad Street
Conference Room: Chesapeake C
Richmond, VA 23220

REGISTER NOW TO RESERVE YOUR SPOT!

To register for this program, visit www.CoriumRSVP.com/4727-448
or call 866-927-7529. You may also contact your Corium Representative, Eric Henegar, to register or
with any questions at 757-660-2581 or via email at eric.henegar@coriumintl.com.

This program is intended for US healthcare professionals only. Guests and spouses may not attend this program. US healthcare professionals must provide their NPI and/or State License Number to register for the program

This is not an accredited education program, and no CME credits are offered.

INDICATION

AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including AZSTARYS, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy

Contraindications

- Known hypersensitivity to serdexmethylphenidate, methylphenidate, or other product components. Bronchospasm, rash, and pruritus have occurred with AZSTARYS. Hypersensitivity reactions such as angioedema and anaphylactic reactions have occurred with other methylphenidate products.
- Concomitant treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days, because of the risk of hypertensive crisis.

Corium

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions

- Sudden death has been reported in association with CNS stimulant treatment at recommended doses in pediatric patients with structural cardiac abnormalities or other serious heart problems. In adults, sudden death, stroke, and myocardial infarction have been reported at recommended doses. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmias, coronary artery disease, or other serious heart problems.
- CNS stimulants cause an increase in blood pressure and heart rate. Monitor all patients for hypertension and tachycardia.
- *Exacerbation of Pre-existing Psychosis:* May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. *Induction of a Manic Episode in Patients with Bipolar Disorder:* May induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms, or a family history of suicide, bipolar disorder, or depression). *New Psychotic or Manic Symptoms:* At recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a history of psychotic illness or mania. Discontinue if symptoms occur.
- Cases of painful and prolonged penile erections and priapism have been reported with methylphenidate products. Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed.
- CNS stimulants, including AZSTARYS, are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Carefully observe patients during treatment for digital changes. Further evaluation may be required, including referral.
- CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Monitor height and weight at appropriate intervals in pediatric patients. Treatment may need to be interrupted in children not growing or gaining weight as expected.

Adverse Reactions

- Based on accumulated data from other methylphenidate products, the most common (>5% and twice the rate of placebo) adverse reactions are appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased.

Drug Interactions

- Adjust dosage of antihypertensive drug as needed. Monitor blood pressure.
- Avoid use of AZSTARYS on the day of surgery if halogenated anesthetics will be used.

Please [click here](#) for Full Prescribing Information, including Boxed WARNING.

References: 1. AZSTARYS. Prescribing information. Corium Inc; 2021. 2. Mickle T, Guenther S, Chi G, inventors; KemPharm, Inc, assignee. Methylphenidate-prodrugs, processes of making and using the same. U.S. patent 10,584,113. March 10, 2020.

Corium

© 2021 Corium, Inc. All rights reserved.
AZSTARYS is a trademark of Corium Inc.
COM-AZS-001525 9/21


azstarys™
serdexmethylphenidate
and dexmethylphenidate
26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules